Clinical Scorecard: Patient Casebook Series: Ligneous Conjunctivitis -- Identifying and Treating a Rare Disease

At a Glance

Key Highlights

• Ligneous conjunctivitis is the most common clinical manifestation of PLGD-1, occurring in 81% of patients.
• RYPLAZIM (plasminogen, human-tvmh) is FDA-approved for treating PLGD-1 and has demonstrated lesion resolution and symptom improvement.
• Diagnosis requires high clinical suspicion with confirmatory testing of plasminogen activity and genetic analysis.

Guideline-Based Recommendations

Diagnosis

• Consider PLGD-1 in patients with recurrent or chronic pseudomembranes or pyogenic granuloma-like conjunctival lesions unresponsive to standard treatments.
• Order blood tests to measure plasminogen activity levels as initial screening.
• Perform genetic testing to identify PLG mutations for confirmation.

Management

• Administer RYPLAZIM infusions biweekly as an effective treatment to resolve lesions and improve quality of life.
• Use an injection port to facilitate medication administration and enable home infusions by trained caregivers.
• Avoid relying solely on plasma infusions due to insufficient plasminogen concentration.

Monitoring & Follow-up

• Monitor patients during and for 4 hours after RYPLAZIM infusion for bleeding, especially in those with bleeding diatheses or on anticoagulants.
• Assess for hypersensitivity reactions including anaphylaxis and discontinue treatment if they occur.
• Evaluate plasminogen activity trough levels if clinical efficacy declines or new lesions develop.
• Monitor for respiratory distress due to tissue sloughing in patients with tracheobronchial mucosal lesions.

Risks

• Potential bleeding at active lesion sites or worsening of bleeding unrelated to lesions.
• Risk of transmission of infectious agents due to plasma-derived product.
• Hypersensitivity reactions including anaphylaxis.
• Possible development of neutralizing antibodies, although not observed in trials.
• Elevated D-dimer levels that may interfere with venous thromboembolism screening.

Patient & Prescribing Data

Pediatric and adult patients diagnosed with PLGD-1 exhibiting mucosal ligneous lesions

RYPLAZIM infusions provide rapid symptom relief and lesion resolution, enabling improved daily functioning and participation in activities; home administration by trained caregivers is feasible.

Clinical Best Practices

• Maintain high suspicion for PLGD-1 in atypical or recurrent conjunctivitis cases unresponsive to conventional therapy.
• Coordinate multidisciplinary care among ophthalmologists, geneticists, and infusion specialists.
• Educate patients and families on administration techniques and monitoring for adverse effects.
• Regularly assess treatment efficacy and adjust management based on clinical and laboratory findings.

References

• FDA Approval of RYPLAZIM
• Clinical Trial Data on RYPLAZIM Efficacy
• Plasminogen Activity Testing Recommendations